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In the WHO European Region, COVID-19 surveillance 
was implemented 27 January 2020. We detail the first 
European cases. As at 21 February, nine European 
countries reported 47 cases. Among 38 cases studied, 
21 were linked to two clusters in Germany and France, 
14 were infected in China. Median case age was 
42 years; 25 were male. Late detection of the clusters’ 
index cases delayed isolation of further local cases. 
As at 5 March, there were 4,250 cases.
A cluster of pneumonia of unknown origin was iden-
tified in Wuhan, China, in December 2019 [1]. On 
12 January 2020, Chinese authorities shared the 
sequence of a novel coronavirus termed severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) iso-
lated from some clustered cases [2]. Since then, the 
disease caused by SARS-CoV-2 has been named cor-
onavirus disease 2019 (COVID-19). As at 21 February 
2020, the virus had spread rapidly mostly within China 
but also to 28 other countries, including in the World 
Health Organization (WHO) European Region [3-5]. 
brought to you by COREView metadata, citation and similar papers at core.ac.uk
provided by REPISALUD
2 www.eurosurveillance.org
Here we describe the epidemiology of the first cases 
of COVID-19 in this region, excluding cases reported in 
the United Kingdom (UK), as at 21 February 2020. The 
study includes a comparison between cases detected 
among travellers from China and cases whose infection 
was acquired due to subsequent local transmission.
Surveillance in the WHO European Region
On 27 January 2020, the European Centre for Disease 
Prevention and Control (ECDC) and the WHO Regional 
Office for Europe asked countries to complete a WHO 
standard COVID-19 case report form for all confirmed 
and probable cases according to WHO criteria [6-8]. 
The overall aim of surveillance at this time was to sup-
port the global strategy of containment of COVID-19 
with rapid identification and follow-up of cases linked 
to affected countries in order to minimise onward 
transmission. The surveillance objectives were to: 
describe the key epidemiological and clinical charac-
teristics of COVID-19 cases detected in Europe; inform 
country preparedness; and improve further case detec-
tion and management. Data collected included demo-
graphics, history of recent travel to affected areas, 
close contact with a probable or confirmed COVID-19 
case, underlying conditions, signs and symptoms of 
disease at onset, type of specimens from which the 
virus was detected, and clinical outcome. The WHO 
case definition was adopted for surveillance: a con-
firmed case was a person with laboratory confirmation 
of SARS-CoV-2 infection (ECDC recommended two sep-
arate SARS-CoV-2 RT-PCR tests), irrespective of clinical 
signs and symptoms, whereas a probable case was 
a suspect case for whom testing for SARS-CoV-2 was 
inconclusive or positive using a pan-coronavirus assay 
[8]. By 31 January 2020, 47 laboratories in 31 coun-
tries, including 38 laboratories in 24 European Union 
Figure 
Epidemic curve of reported COVID-19 cases by date of symptom onset, or date of notification, WHO European Region, as 








































































































Case infected in China
Based on date of notification
COVID-19: coronavirus disease 2019; WHO: World Health Organization.
a Four cases were reported by Germany with unknown date of onset and unknown symptomatology. Belgium and France reported one 
asymptomatic case each. These cases are displayed according to their date of notification.
b The figure does not include nine cases reported in the United Kingdom.
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and European Economic Area (EU/EEA) countries, had 
diagnostic capability for SARS-CoV-2 available (close 
to 60% of countries in the WHO European Region), with 
cross-border shipment arrangements in place for many 
of those lacking domestic testing capacity. The remain-
ing six EU/EEA countries were expected to have diag-
nostic testing available by mid-February [9].
Epidemiology of first cases in the European 
Region
As at 09:00 on 21 February 2020, 47 confirmed cases 
of COVID-19 were reported in the WHO European 
Region and one of these cases had died [4]. Data on 38 
of these cases (i.e. all except the nine reported in the 
UK) are included in this analysis.
The first three cases detected were reported in France 
on 24 January 2020 and had onset of symptoms on 17, 
19 and 23 January respectively [10]. The first death was 
reported on 15 February in France. As at 21 February, 
nine countries had reported cases (Figure): Belgium (1), 
Finland (1), France (12), Germany (16), Italy (3), Russia 
(2), Spain (2), Sweden (1) and the UK (9 – not included 
further). 
The place of infection (assessed at national level based 
on an incubation period presumed to be up to 14 days 
[11], travel history and contact with probable or con-
firmed cases as per the case definition) was reported 
for 35 cases (missing for three cases), of whom 14 were 
infected in China (Hubei province: 10 cases; Shandong 
province: one case; province not reported for three 
cases). The remaining 21 cases were infected in 
Europe. Of these, 14 were linked to a cluster in Bavaria, 
Germany, and seven to a cluster in Haute-Savoie, 
France [12,13]. Cases from the Bavarian cluster were 
reported from Germany and Spain, whereas cases from 
the Haute-Savoie cluster were reported from France 
Table
Characteristics of confirmed COVID-19 cases, WHO European Region, as at 21 February 2020 (n = 38)a
Characteristics Number of cases overall Number of cases infected in Europe
Number of cases infected 
in China p value
b
Age range in years
    0–17 4 3 0
0.08
    18–49 24 13 9
    50–64 7 5 2
    ≥ 65 3 0 3
Sex
    Male 25 14 8
0.6
    Female 13 7 6
Hospitalised
    Yes 35 21 14
ND    No 2 ND ND
    Unknown 1 ND ND
Symptomsc (31 cases with available information)
    Asymptomatic 2 ND ND
ND
    Fever 20 ND ND
    Cough 14 ND ND
    Weakness 8 ND ND
    Headaches 6 ND ND
    Sore throat 2 ND ND
    Rhinorrhoea 2 ND ND
    Shortness of breath 2 ND ND




3.7 4.6 2.5 ND




5.1 6.5 5.2 ND
COVID-19: coronavirus disease 2019; ND: not determined or known; WHO: World Health Organization.
a The Table does not include nine cases reported in the United Kingdom.
b Chi-squared test for difference in distributions between cases infected in Europe and those infected in China.
c A single case could have more than one symptom. Only symptoms reported by two or more cases shown.
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and Spain. Cases linked to the Haute Savoie cluster 
were also detected in the UK, including the index case 
of this cluster, who was infected in Singapore before 
travelling to France [14]. The index cases for the cluster 
in Bavaria was reported to be infected in China [15].
The median age of the 38 cases was 42 years (range: 
2–81 years) and 25 were male (Table). The proportion of 
male cases was higher among cases acquired in Europe 
(14 males of 21 cases) compared with those acquired 
in China (8 males of 14 cases) although the differ-
ence was not statistically significant (chi-squared test: 
p = 0.6). There was no difference in median age by sex 
(males: 45 years; females: 38 years, k-sample median 
test, p = 1.0) or by whether infection was acquired in 
Europe or not (acquired in Europe: 47 years; acquired in 
China: 38 years, p = 0.2).
All but two cases were hospitalised (35 of 37 where 
information on hospitalisation was reported), although 
it is likely that most were hospitalised to isolate the 
person rather than because of severe disease. The 
time from onset of symptoms to hospitalisation (and 
isolation) ranged between 0 and 10 days with a mean 
of 3.7 days (reported for 29 cases). The mean num-
ber of days to hospitalisation was 2.5 days for cases 
imported from China, but 4.6 days for those infected in 
Europe. This was mostly a result of delays in identify-
ing the index cases of the two clusters in France and 
Germany. In the German cluster, for example, the first 
three cases detected locally were hospitalised in a 
mean of 5.7 days, whereas the following six took only a 
mean of 2 days to be hospitalised.
Symptoms at the point of diagnosis were reported for 
31 cases. Two cases were asymptomatic and remained 
so until tested negative. The asymptomatic cases were 
tested as part of screening following repatriation and 
during contact tracing respectively. Of the remaining 
29, 20 reported fever, 14 reported cough and eight 
reported weakness. Additional symptoms reported 
included headaches (6 cases), sore throat (2), rhinor-
rhoea (2), shortness of breath (2), myalgia (1), diar-
rhoea (1) and nausea (1). Fever was reported as the 
sole symptom for nine cases. In 16 of 29 symptomatic 
cases, the symptoms at diagnosis were consistent with 
the case definition for acute respiratory infection [16], 
although it is possible that cases presented additional 
symptoms after diagnosis and these were not reported.
Data on pre-existing conditions were reported for 
seven cases; five had no pre-existing conditions while 
one was reported to be obese and one had pre-existing 
cardiac disease. No data on clinical signs e.g. dyspnea 
etc. were reported for any of the 38 cases.
All hospitalised cases had a benign clinical evolution 
except four, two reported in Italy and two reported in 
France, all of whom developed viral pneumonia. All 
three cases who were aged 65 years or over were admit-
ted to intensive care and required respiratory support 
and one French case died. The case who died was hos-
pitalised for 21 days and required intensive care and 
mechanical ventilation for 19 days. The duration of hos-
pitalisation was reported for 16 cases with a median of 
13 days (range: 8–23 days). As at 21 February 2020, four 
cases were still hospitalised.
Laboratory diagnosis
All cases were confirmed according to specific assays 
targeting at least two separate genes (envelope (E) 
gene as a screening test and RNA-dependent RNA 
polymerase (RdRp) gene or nucleoprotein (N) gene for 
confirmation) [8,17]. The specimen types tested were 
reported for 27 cases: 15 had positive nasopharyngeal 
swabs, nine had positive throat swabs, three cases 
had positive sputum, two had a positive nasal swab, 
one case had a positive nasopharyngeal aspirate and 
one a positive endotracheal aspirate.
Discussion
As at 09:00 on 21 February, few COVID-19 cases had 
been detected in Europe compared with Asia. However 
the situation is rapidly developing, with a large out-
break recently identified in northern Italy, with trans-
mission in several municipalities and at least two 
deaths [18]. As at 5 March 2020, there are 4,250 cases 
including 113 deaths reported among 38 countries in 
the WHO European region [19].
In our analysis of early cases, we observed transmis-
sion in two broad contexts: sporadic cases among trav-
ellers from China (14 cases) and cases who acquired 
infection due to subsequent local transmission in 
Europe (21 cases). Our analysis shows that the time 
from symptom onset to hospitalisation/case isolation 
was about 3 days longer for locally acquired cases than 
for imported cases. People returning from affected 
areas are likely to have a low threshold to seek care 
and be tested when symptomatic, however delays in 
identifying the index cases of the two clusters in France 
and Germany meant that locally acquired cases took 
longer to be detected and isolated. Once the exposure 
is determined and contacts identified and quarantined 
(171 contacts in France and 200 in Germany for the clus-
ters in Haute-Savoie and Bavaria, respectively), further 
cases are likely to be rapidly detected and isolated when 
they develop symptoms [15,20]. In the German cluster, 
for example, the first three cases detected locally were 
hospitalised in a mean of 5.7 days, whereas the follow-
ing six were hospitalised after a mean of 2 days. Locally 
acquired cases require significant resources for contact 
tracing and quarantine, and countries should be pre-
pared to allocate considerable public health resources 
during the containment phase, should local clusters 
emerge in their population. In addition, prompt shar-
ing of information on cases and contacts through inter-
national notification systems such as the International 
Health Regulations (IHR) mechanism and the European 
Commission’s European Early Warning and Response 
System is essential to contain international spread of 
infection.
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All of the imported cases had a history of travel to 
China. This was consistent with the epidemiological 
situation in Asia, and supported the recommendation 
for testing of suspected cases with travel history to 
China and potentially other areas of presumed ongo-
ing community transmission. The situation has evolved 
rapidly since then, however, and the number of coun-
tries reporting COVID-19 transmission increased rap-
idly, notably with a large outbreak in northern Italy with 
3,089 cases reported as at 5 March [18,19]. Testing of 
suspected cases based on geographical risk of impor-
tation needs to be complemented with additional 
approaches to ensure early detection of local circula-
tion of COVID-19, including through testing of severe 
acute respiratory infections in hospitals irrespectively 
of travel history as recommended in the WHO case def-
inition updated on 27 February 2020 [21].
The clinical presentation observed in the cases 
in Europe is that of an acute respiratory infection. 
However, of the 31 cases with information on symp-
toms, 20 cases presented with fever and nine cases 
presented only with fever and no other symptoms. 
These findings, which are consistent with other pub-
lished case series, have prompted ECDC to include 
fever among several clinical signs or symptoms indica-
tive for the suspected case definition.
Three cases were aged 65 years or over. All required 
admission to intensive care and were tourists (imported 
cases). These findings could reflect the average older 
age of the tourist population compared with the local 
contacts exposed to infection in Europe and do not 
allow us to draw any conclusion on the proportion of 
severe cases that we could expect in the general popu-
lation of Europe. Despite this, the finding of older indi-
viduals being at higher risk of a severe clinical course is 
consistent with the evidence from Chinese case series 
published so far although the majority of infections in 
China have been mild [22,23].
This preliminary analysis is based on the first reported 
cases of COVID-19 cases in the WHO European Region. 
Given the small sample size, and limited completeness 
for some variables, all the results presented should be 
interpreted with caution.
With increasing numbers of cases in Europe, data from 
surveillance and investigations in the region can build 
on the evidence from countries in Asia experiencing 
more widespread transmission particularly on disease 
spectrum and the proportion of infections with severe 
outcome [22]. Understanding the infection-severity is 
critical to help plan for the impact on the healthcare 
system and the wider population. Serological studies 
are vital to understand the proportion of cases who are 
asymptomatic. Hospital-based surveillance could help 
estimate the incidence of severe cases and identify 
risk factors for severity and death. Established hospi-
tal surveillance systems that are in place for influenza 
and other diseases in Europe may be expanded for this 
purpose. In addition, a number of countries in Europe 
are adapting and, in some cases, already using existing 
sentinel primary care based surveillance systems for 
influenza to detect community transmission of SARS-
CoV-2. This approach will be used globally to help 
identify evidence of widespread community transmis-
sion and, should the virus spread and containment no 
longer be deemed feasible, to monitor intensity of dis-
ease transmission, trends and its geographical spread.
Additional research is needed to complement surveil-
lance data to build knowledge on the infectious period, 
modes of transmission, basic and effective reproduc-
tion numbers, and effectiveness of prevention and 
case management options also in settings outside of 
China. Such special studies are being conducted glob-
ally, including a cohort study on citizens repatriated 
from China to Europe, with the aim to extrapolate dis-
ease incidence and risk factors for infection in areas 
with community transmission. Countries together 
with ECDC and WHO, should use all opportunities to 
address these questions in a coordinated fashion at 
the European and global level.
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